Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Camanio Care’s rights issue is covered by 100% subscription commitments, and additional information regarding the rights issue

The ongoing rights issue has received subscription commitments of 5,2 million SEK. In addition, there is an ongoing oversubscription rights issue of 2 million SEK. In connection to information regarding subscription commitments, updated information about the use of the issue amount, as well as the company’s financial situation, will be provided.Of the received subscription commitments in the rights issue, 2,3 million SEK concerns subscriptions with preferential rights and 2,9 million SEK concerns subscriptions without preferential rights. Of the received subscription commitments in the

Additional order from US defense company

Linköping, Sweden—XMReality AB (publ) (NASDAQ First North: XMR), an international leader in AR-enabled knowledge sharing, has signed a follow-up order with a US defense company group. The order includes software and AR glasses and is worth approx. 0,5 MSEK. Delivery will take place during 2018 and 2019.XMReality has signed a third order to improve the service operations for an US defense company. The order includes XMReality Remote Guidance™ software, XMReality PointPad™ and AR glasses with a value of approx. 0,5 MSEK and revenues will be recognized during 2018 and 2019. Including this

Epiroc launches new generation battery-driven machines for sustainable mining

Stockholm, Sweden: Epiroc, a leading productivity partner for the mining, infrastructure and natural resources industries, today launches its second generation of battery-operated machines that will lower mining customers’ costs and promote a healthier work environment.The battery-driven underground loaders, trucks and drill rigs launched today will create a number of benefits for mining companies globally, including improved health and safety, reduced greenhouse gas emissions and lower operating costs.  “We at Epiroc want to help our customers boost productivity, enhance safety and cut

ChromoGenics informs of previously received order of approximately SEK 3.3 million to Coop in Norway

ChromoGenics AB (publ) has signed an agreement with the construction company BYGG Engineering AS to deliver ConverLight® dynamic glass and installation to a Coop store in Tverlandet, Bodö, Norway.The order was acknowledged in late September and was communicated in the Q3 report, but has not been able to be communicated separately until now due to technical and administrative clarifications. The project is a new construction project of a shopping mall with Coop as a builder with the ambition to build energy efficiently, with great focus on interior comfort and architectural design. The

Interim report July - September 2018

Third quarter ·  Net sales amounted to MSEK 3.2 (13.7) ·  EBITDA amounted to MSEK -7.4 (13.7) ·  EBIT amounted to MSEK -10.3 (10.7) ·  EBT amounted to MSEK -10.4 (4.6) ·  Earnings per share before dilutions amounted to SEK -0.23 (0.09) ·  Appointed Torkel Johannessen as new CEO First nine months ·  Net sales amounted to MSEK 16.8 (70.5) ·  EBITDA amounted to MSEK -15.7 (18.0) ·  EBIT amounted to MSEK -23.3 (5.1) ·  EBT amounted to MSEK -27.2 (-6.7) ·  Earnings per share before dilutions amounted to SEK -0.58 (-0.22) Significant events after the

Sedana Medical shows significant health-economic benefits with AnaConDa

Sedana Medical AB (publ) (Sedana Medical or the company) presents a health economic analysis at the European Conference for Health Economics and Outcomes Research 2018 (ISPOR) in Barcelona, showing clinical and economic benefits of inhaled isoflurane sedation via AnaConDa versus conventional intravenous sedation with propofol or midazolam.The analysis model has been developed to compare the costs and clinical outcome of sedated and ventilated intensive care patients. Clinical data is derived from a German retrospective study (Bellgardt et al., Eur J Anaesthesiology 2016, 33: 6-13), that

ABB expands transformer portfolio with launch of new products

New range of products to facilitate digitalization of grids and offer enhanced safety, efficiency and reliabilityABB today launched the world’s first dry-type (oil free) digital transformer, named the ABB Ability™ TXpert™ Dry, and another innovative product called TXpand™ at its ABB Customer World (ACW) event in Xiamen, China. The ABB Ability™ TXpert™ Dry incorporates digital capability within ABB’s proven dry-type transformers. Transformers typically use oil for cooling and insulation but dry-type transformers are designed to work without oil, where the core and the coil are cooled by

Triton completes the acquisition of a majority stake in Norres Group

Frankfurt / Gelsenkirchen (Germany), 14 November 2018 – The Smaller Mid Cap Fund advised by Triton (“Triton”) has completed the acquisition of a majority stake in NORRES Group (“NORRES”), one of Europe’s market leading manufacturer of plastic industrial hoses headquartered in Gelsenkirchen, Germany. "We want to support NORRES by investing in accelerated growth and continuous internationalisation of the company. We look forward to working together with the management team and contribute our expertise and available resources to promote our common vision of an even stronger company," said

#18-2147 Recalculation of reference value for certain instrument with General Electric Company as underlying security

The reference value for certain certificate with General Electric Company as underlying security has been recalculated in accordance with the instruments final terms. This applies to the following instrument: Symbol: BEAR GE X8 C Symbol: BEAR GE X10 C The instrument will be traded under observation for the duration of this trading day. For more information concerning the recalculation, please contact the issuer of the affected instrument.For further information concerning this NGM notice please contact: NGM market surveillance, +46 8 566 390 55, marketsurveillance@ngm.se

#18-2146 Recalculation of reference value for certain instrument with Brent Crude Oil Future and WTI Light Sweet Crude Oil Future as underlying security

The reference value for certain certificate with Brent Crude Oil Future and WTI Light Sweet Crude Oil Future as underlying security has been recalculated in accordance with the instruments final terms. This applies to the following instrument: Symbol: BULL WTI X12 VON2 Symbol: BULL OLJY X12 V5 Symbol: BULL OLJA X12 VON5 Symbol: BULL WTI X12 V4 Symbol: BULL WTI X12 VON4 Symbol: BULL WTI X12 V3 Symbol: BULL WTI X12 V5 Symbol: BULL WTI X12 VON3 Symbol: BULL OLJA X12 VON3 Symbol: BULL OLJA X12 VON4 Symbol: BULL OLJY X12 V3 Symbol: BULL OLJY X12 V4 Symbol:

Terveystalo Plc: Financial calendar and AGM in 2019

Terveystalo Plc Stock Exchange Release 14 November 2018 at 09:05 a.m. EET In 2019, Terveystalo Plc will publish financial reports as follows: · Financial Statements Bulletin 2018 on Thursday, February 14, 2019 · Annual Report 2018 on week 9, 2019 · Interim report for January-March 2019 on Thursday, May 9, 2019 · Half-Year Report for January-June 2019 on Thursday, August 8, 2019 · Interim report for January-September 2019 on Thursday, October 31, 2019 The Financial Statements Bulletin 2018 and financial reviews 2019 will be published at approximately 9:00 a.m. EET.

SinterCast Results July-September 2018

Year-on-year series production increases by 15% as earnings per share grows by 43% Third Quarter 2018 · Revenue for Period: SEK 19.7 million (SEK 16.7 million) · Operating Result: SEK 6.0 million (SEK 4.7 million) · Earnings per Share: SEK 1.0 per share (SEK 0.7 per share) · Cashflow from Operations: SEK 9.9 million (SEK 1.0 million) · Start of production of passenger vehicle in-line diesel engine; shipments to begin in fourth quarter · Poitras Foundry in Canada orders SinterCast Ladle Tracker®installation for ductile iron production · Kimura Foundry in Japan

Invitation to telephone conference / audiocast – Q3 2018 Report

Boozt AB’s (publ) quarterly 2018 report will be published on Wednesday the 21st of November at 08.00 CET.At 09.30 CET on the same day, Boozt’s CEO, Hermann Haraldsson, and CFO, Allan Junge-Jensen, will present the Interim Report at a telephone conference / audiocast. The presentation will be held in English and will be followed by a Q&A session. Questions can be asked via the telephone conference or in written form via the audiocast. No registration is needed. The presentation material will be available at Boozt’s website . How to participate in the

Interim Report July-September 2018

Clinical trials on track Stockholm, 14 November, 2018: Asarina Pharma AB releases its Interim Report for 1 July – 30 September, 2018.Third Quarter Highlights · Asarina’s Phase IIB study in PMDD (Premenstrual Dysphoric Disorder) progressed during the third quarter with a steady increase in the recruitment of patients. The company expects as previously communicated to have topline results before year-end 2019. · During the third quarter, the Company intensified its preparations for the phase IIA study in menstrual migraine. The study will be initiated in the second quarter of 2019

Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)

The shareholders of Calliditas Therapeutics AB (publ) are summoned to the extraordinary shareholders’ meeting on Friday 14 December 2018 at 3 p.m. at Apotekarsocieteten, Wallingatan 26A, Stockholm, Sweden. Registration starts at 2 p.m. Right to attend the extraordinary shareholders’ meeting Shareholders who wish to attend the extraordinary shareholders’ meeting must -        be registered in the share register maintained by Euroclear Sweden AB on Saturday8 December 2018 (please note that as the record day is a Saturday, the shareholders must be entered into the share register

Welcome to attend MAG Interactive AB (PUBL)´s Annual General Meeting

MAG Interactive AB (publ) hereby gives notice of its Annual General Meeting to be held at 10:00 am, Tuesday 18 December 2018 at 7A Odenplan, address Norrtullsgatan 6, Stockholm, Sweden. The convention hall opens for registration to the Annual General Meeting at 09:30 am.Participation Any person is entitled to participate at the Annual General Meeting if they areentered in the share register maintained by Euroclear Sweden AB on Wednesday, 12 December 2018; andhave notified the company of their intention to participate at the latest on Wednesday, 12 December 2018 in one of the

Rungne Exploration Well Results

14 November 2018  Faroe Petroleum plc  ("Faroe", "Faroe Petroleum", the "Company")    Rungne Exploration Well Results  Faroe Petroleum, the independent oil and gas company focusing principally on exploration, appraisal and production opportunities in Norway and the UK, announces the results of the Faroe-operated Rungne exploration well 30/6-30 in the Norwegian North Sea (Faroe 40% working interest).  The well encountered a 56 metre gross (17 metre net) gas/condensate column in good quality interbedded Middle Jurassic Ness formation sandstones and 86 metres of gross water

GenesisCare signs MoU for Versa HD cancer treatment systems and research agreement with Elekta

Australia and Europe’s largest private provider of cancer care expands investment in Elekta’s innovative radiation therapy solutions and investigates potential to treat benign diseasesSTOCKHOLM, November 14, 2018 – Elekta (EKTA-B.ST) announced today that GenesisCare has signed a Memorandum of Understanding (MoU) for Elekta Versa HD™ linear accelerators (linacs) to deliver radiation therapy across its growing network of oncology centers in Australia, the UK, Spain, and soon in China and South East Asia. It is valued at approximately USD 60 million. The MoU includes provisions for Elekta’s

Kesko’s sales grew in October

The sales of Kesko Group’s continuing operations in October 2018 totalled €947.6 million, representing an increase of 6.1% in comparable terms. The reported sales from continuing operations increased by 5.5%. The month had one wholesale selling day more than the year before. "Sales grew in the grocery trade and in the building and technical trade. In the car trade, sales decreased due to the implementation of the new WLTP emissions testing in Europe," says Mikko Helander, Kesko’s President and CEO. Sales in the grocery trade totalled €471.1 million in October, an increase of 7.6% in

Neste MY Renewable Diesel launched in Latvia

Neste Corporation Press Release 14 November 2018 at 9 am. (EET) Neste, Latvia’s leading network of automatic filling stations, has launched Neste MY Renewable Diesel ™ for the Latvian transport market. It is produced from 100% renewable raw materials and enables up to 90% less greenhouse gas emissions compared to conventional fossil diesel. The product is available at the Neste filling station at 84 Ulmaņa gatves Street in Riga. “Climate change is one of the biggest challenges of our time. Neste MY Renewable Diesel gives our climate-

Eltel’s Power business in Finland signs two-year frame agreement worth EUR 13.6 million

Eltel’s Power business in Finland has signed a two-year frame agreement with Caruna, a Finnish energy company, to ensure a reliable power distribution. The agreement is worth about EUR 13.6 million.The frame agreement is based on a geographical model where Eltel’s Power business is responsible for field services for Caruna’s end customers, distribution network fault repairs as well as maintenance and construction works in awarded municipalities.  The frame agreement is valid for two years from March 2019 until the end of March 2021.   The agreement covers Espoo, Kirkkonummi and

Clinical trial of Inofer: half of the patients already recruited

The tenth patient of twenty has now been recruited for the clinical study of the iron tablets Inofer, which Drugsson AB (subsidiary of Double Bond Pharmaceutical) has the rights to in Sweden, Norway, Denmark and Finland. This means that the study is proceeding according to plan. The clinical trial of Inofer was approved as previously reported, by the Swedish Medical Products Agency and the Ethical vetting board on 20 June, commencing on October 4 when the first patient received treatment with Inofer tablets. The study is conducted at Skellefteå Hospital and is led by chief physician Kurt

Terveystalo Group Interim Report 1 January - 30 September 2018

Terveystalo Plc. Interim report 14 November 2018 at 9:00 a.m. EET Strong earnings trend continued July-September 2018 in brief · Revenue increased by 3.2 percent year-on-year to EUR 160.3 million (155.4)  · Adjusted* EBITDA increased by 15.2 percent year-on-year to EUR 20.1 million (17.5)  · EBITDA more than tripled year-on-year to EUR 27.6 million (7.6)  · Adjusted* earnings before interest, taxes, and amortization (EBITA) were 9.2 percent (8.0) of revenue  · Earnings before interest, taxes, and amortization (EBITA) were 13.9 (1.7) percent of revenue  · Profit for

There are no items matching the current filter
There are no more items matching the current filter
Back to top